You are here
Thursday, September 2, 2010
Lower blood pressure goal benefits African-Americans with chronic kidney disease, protein in the urine
On average, a lower blood pressure goal was no better than the standard blood pressure goal at slowing progression of kidney disease among African-Americans who had chronic kidney disease resulting from high blood pressure, according to results of the African-American Study of Kidney Disease and Hypertension (AASK), the largest and longest study of chronic kidney disease (CKD) in African-Americans. However, the blood pressure goal did benefit people who also had protein in the urine, which is a sign of kidney damage. The study, funded by the National Institutes of Health, appears in the Sept. 2 issue of the New England Journal of Medicine.
The AASK also found that among people with protein in their urine, keeping blood pressure at the lower level reduced the likelihood of kidney disease progression, kidney failure or death by 27 percent compared to the standard blood pressure level, a statistically significant difference.
"For some patients, more intensive control of blood pressure may slow progression of chronic kidney disease," said Griffin P. Rodgers, M.D., director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the NIH. "Rigorous, long-term studies like the AASK remain critically important for improving treatment of CKD and other diseases that develop over time, as it can take years for benefits of treatment to emerge."
AASK adds new information about which CKD patients benefit from lowering of blood pressure. This information may help doctors practice evidence-based, personalized medicine, the tailoring of each treatment regimen to each patient's unique characteristics. AASK followed participants for approximately 12 years to measure the long-term effects of blood pressure control in African-Americans with kidney disease attributed to high blood pressure.
The study was conducted in two phases. First, in a clinical trial from 1995 to 1998, participants were randomly assigned to a standard blood pressure goal of roughly 140/90 mmHg (usual) or a lower goal of less than 130/80 mmHg. After the clinical trial was completed, most of the remaining participants were enrolled in a follow-up study in which everyone had a blood pressure goal of less than 130/80 mm/Hg.
"The AASK study is the largest and longest study of kidney disease in African-Americans. It is a landmark study that is paying off - guiding patient care and improving health outcomes," said Lawrence Appel, M.D. of Johns Hopkins University, Baltimore, who chaired the study. "This study also highlights the importance of conducting long-term clinical studies. Without the follow-up study, the benefits of the lower goal would have been missed."
In the United States, high blood pressure causes about one third of new cases of kidney failure, also known as end-stage renal disease (ESRD). The cost to the government and private payers for ESRD now exceeds $35 billion annually.
"For nearly two decades, the AASK research has provided valuable information about the most desirable, long-term chronic kidney disease treatment options for African-Americans, who bear a disproportionate burden of this debilitating disease," said Lawrence Agodoa, M.D., director of the Office of Minority Health Research Coordination at the NIDDK. "People who participate in studies like AASK provide important information on how to protect the kidneys and preserve overall health."0
Study participants were initially recruited beginning in 1995 for the AASK Clinical Trial www.nih.gov/news/pr/nov2002/niddk-25.htm. Patients with diabetes and some other serious health problems were excluded. After the conclusion of that study, AASK participants who had not yet developed ESRD were invited to participate in the AASK follow-up study, which started in 2002.
In the follow-up study, recommended blood pressure therapy started with an angiotensin converting enzyme (ACE) inhibitor. This medication works by blocking the action of the protein angiotensin, which raises blood pressure. If blood pressure was not controlled, additional drugs were added. On average, patients needed about 3.5 medications for blood pressure each day. Millions of Americans take the drugs used in this study or drugs like them to treat health problems like high blood pressure or heart disease.
The AASK trial and the follow-up study were conducted at 22 U.S. medical centers and were funded by NIDDK beginning in 1994. Additional support was provided by the NIH's National Institute on Minority Health and Health Disparities (NIMHD), King Pharmaceuticals and other pharmaceutical companies that donated study drugs.
For a list of centers enrolling patients for kidney disease trials, search keywords "kidney disease" at www.clinicaltrials.gov.
For NIDDK materials about high blood pressure and kidney disease, visit www.kidney.niddk.nih.gov/kudiseases/pubs/highblood/index.htm.
The NIDDK, part of the NIH, conducts and supports basic and clinical research and research training on some of the most common, severe and disabling conditions affecting Americans. The Institute's research interests include diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition and obesity; and kidney, urologic and hematologic diseases. For more information, visit www.niddk.nih.gov.
The NIMHD (formerly NCMHD) promotes minority health and leads, coordinates, supports, and assesses the NIH effort to reduce and ultimately eliminate health disparities. NIMHD conducts and supports basic, clinical, social, and behavioral research, promotes research infrastructure and training, fosters emerging programs, disseminates information, and reaches out to minority and other health disparity communities. Visit www.ncmhd.nih.gov.
To interview the lead author, Dr. Lawrence J. Appel at Johns Hopkins University, Baltimore, contact Stephanie Desmon Fey at 410-955-8665 or mailto:email@example.com.
To interview NIDDK Director Dr. Griffin Rodgers, contact Bill Polglase at 301-496-3583 or firstname.lastname@example.org.
Editor's Note: Facilities that are currently participating in the AASK are:
The Cleveland Clinical Foundation, Ohio (data coordinating center); University of Alabama, Birmingham; King-Drew Medical College, Los Angeles; University of Southern California, Los Angeles; University of California, San Diego; Harbor-UCLA Medical Center, Torrance, California; Howard University Hospital, Washington, D.C.; University of Florida, Gainesville; University of Miami; Morehouse School of Medicine, Atlanta; Emory University, Decatur, Georgia; Rush Presbyterian St. Luke’s Medical Center, University of Illinois, Chicago; The Johns Hopkins University, Baltimore; University of Michigan, Ann Arbor; Harlem Hospital Center, New York; Mount Sinai School of Medicine, New York; Case Western Reserve University, Cleveland; Ohio State University, Columbus; Medical University of South Carolina, Charleston; Meharry Medical College, Nashville, Tennessee; Vanderbilt University, Nashville, Tennessee; and the University of Texas Southwestern Medical Center, Dallas.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®